Condition 1: Breast cancer. Condition 2: Radiation Dermatitis. Malignant neoplasm of breast Acute radiodermatitis
Conditions
Interventions
Intervention 1: Intervention group: Three 500 mg Glucophage (metformin) tablets (licensed by Merck) will be taken daily for 30 days (from one day before the start of radiotherapy to one day after the
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients diagnosed with breast cancer Eligible for adjuvant therapy
Exclusion criteria
Exclusion criteria: Has a history of receiving radiation therapy to the chest area Skin allergies Has a history of lactic acidosis (caused by liver or kidney problems) History of systemic or skin diseases, such as diabetes Patients with collagen vascular disease, or taking medications that affect wound healing, such as systemic steroids
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Radiation dermatitis. Timepoint: Start of measurement: End of the first week of radiotherapy, which is usually equivalent to the end of the fifth session of radiotherapy. Measurement frequency: Once every five sessions. End of measurement: One week after the end of radiotherapy. Method of measurement: Using WHO dermatitis score criteria and tables and by a specialist doctor.;Radiotoxicity. Timepoint: Start of measurement: End of the first week of radiotherapy, which is usually equivalent to the end of the fifth session of radiotherapy. Measurement frequency: Once every five sessions. End of measurement: One week after the end of radiotherapy. Method of measurement: Using WHO dermatitis score criteria and tables and by a specialist doctor. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSeyyed Mohammad Hossein Afzali-Joibari
Shiraz University of Medical Sciences
Outcome results
None listed